FeesSafety
Pluang+

PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer, plans NDA filing in early 2027.

Company Fundamentals
20 Nov 2026, 17:30 WIB
GlobeNewsWire
View Source
Bullish
PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer, plans NDA filing in early 2027.

PMV Pharmaceuticals announced promising Phase 2 trial results for rezatapopt, a targeted therapy for TP53 Y220C-mutated advanced solid tumors. In 65 patients with platinum-resistant ovarian cancer, the drug showed a 48% overall response rate with a median response duration of 10.4 months. Across 168 patients with various tumors, the response rate was 36%. The company plans to submit a New Drug Application (NDA) for platinum-resistant ovarian cancer in the first quarter of 2027. The treatment demonstrated a manageable safety profile and offers a potential chemotherapy-free oral option for patients.

PMV Pharmaceuticals' updated Phase 2 trial data on rezatapopt provides context for health-sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 20, 2026 22:11 WIB: Among 150 priced US health-sector stocks, 99 rose and 50 fell. Notable movers include MRNA at USD 209.20 with a 4.95% gain and a typical hold time of 59 days, AMWL at USD 10.17 down 4.86%, and UNH at USD 346.00 up 4.70% with a typical hold time of 99 days and Pluang order activity showing 67% buy interest.

More News

BitFuFu Q3 EPS beats estimates at $0.14, but revenue misses at $37.7M amid Bitcoin price drop.

BitFuFu Q3 EPS beats estimates at $0.14, but revenue misses at $37.7M amid Bitcoin price drop.

BitFuFu reported Q3 2026 earnings with an EPS of $0.14, surpassing the $0.03 estimate, while revenue fell short at $37.7 million versus the expected $42.7 million. The revenue decline reflects a 38% drop in Bitcoin prices, lower cloud mining demand, ...

Company Fundamentals
Neutral
1 hour ago
Asia-Pacific companion animal diagnostics market to hit $1.65B by 2031 with 10.2% CAGR driven by AI and pet care trends

Asia-Pacific companion animal diagnostics market to hit $1.65B by 2031 with 10.2% CAGR driven by AI and pet care trends

The Asia-Pacific companion animal diagnostics market is projected to grow from $840 million in 2024 to $1.65 billion by 2031, at a CAGR of 10.2%. Growth is fueled by rising pet ownership, increased awareness of animal health, and advances in veterina...

Market News
Bullish
1 hour ago
Global multi-omics market to grow to $28.6B by 2036, driven by AI and precision medicine advances

Global multi-omics market to grow to $28.6B by 2036, driven by AI and precision medicine advances

The global multi-omics market, valued at $8.6 billion in 2025, is projected to reach $28.6 billion by 2036 with a CAGR of 10.6%. Growth is fueled by advances in AI, precision medicine, sequencing technologies, and increased investment in drug discove...

Market News
Bullish
1 hour ago
Longevity tech market to hit $44.18B by 2036, driven by AI, regenerative medicine, and aging biology advances

Longevity tech market to hit $44.18B by 2036, driven by AI, regenerative medicine, and aging biology advances

The global longevity technologies market is projected to grow from $9.64 billion in 2026 to $44.18 billion by 2036, at a CAGR of 16.4%. Growth is fueled by advances in AI-driven drug discovery, regenerative medicine, biomarker diagnostics, and a deep...

Market News
Bullish
1 hour ago
Global induction furnaces market to reach $4.2B by 2036, driven by green tech and AI innovations.

Global induction furnaces market to reach $4.2B by 2036, driven by green tech and AI innovations.

The global induction furnaces market, valued at $2.4 billion in 2025, is projected to grow to $4.2 billion by 2036 with a 5.2% CAGR. Growth is fueled by industrial electrification, decarbonization efforts, metal recycling, and advances in energy-effi...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App